A Phase I Study of PLX038 in Patients With Advanced Solid Tumors

Summary

This is a Phase I, open-label, two-arm, dose escalation study of PLX038 intravenous infusion administered to patients with refractory or relapsed solid tumors. This study will explore two different dosing schedules: Arm 1, once every 3 week (q3w), and Arm 2, once weekly for 2 consecutive weeks of a 4-week cycle.

Timeline

Start

2016-03

Primary completion

2023-02

Completion

2023-07

Drugs

Indications